Guofeng Cheng
程国锋
Guofeng Cheng is a biotech entrepreneur and the co-founder and CEO of AusperBio (浩博医药), a company developing treatments for hepatitis B and other liver diseases. He holds a PhD and has led AusperBio through multiple funding rounds, including a $63 million Series B2 in 2025 co-led by Qiming Venture Partners and a subsequent financing in 2026 that the firm described as an important milestone . Under his leadership, AusperBio has advanced its lead candidate AHB-171 into clinical trials, with the first patient dosed in 2026 , and presented data at the HEP-DART conference later that year .
AI-generated — may contain errors, please verify.
Coverage
Qiming Venture Partners Weekly: Top 10 Portfolio Company Updates Vol. 28, Sep. 2, 2026
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol.25, 2026.8.11
Following Qiming Venture Partners' portfolio companies as they hit milestone moments.
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 44, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
AusperBio raises $63M in Series B2 funding co-led by Qiming Venture Partners
Haibo Pharmaceutical is a clinical-stage innovative drug company focused on the R&D of self-developed targeted small nucleic acid therapeutics, with "achieving clinical cure for chronic hepatitis B" as its core mission.
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 16, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
